The growth of xenografts in the three groups was monitored and shown in Figure 7A. The result, in agreement with in vitro data, suggests that E3330, in combination with EGFR‐TKI, suppresses EGFR‐TKI‐resistant cancer cell growth (P < 0.01), whereas the tumor continues vigorously growing in the EGFR‐TKI alone treated group and vehicle control group. Here, EGFR is linked to neoplasm.